EG18951A - Process for preparing pyrrolidine derivatives - Google Patents

Process for preparing pyrrolidine derivatives

Info

Publication number
EG18951A
EG18951A EG17090A EG17090A EG18951A EG 18951 A EG18951 A EG 18951A EG 17090 A EG17090 A EG 17090A EG 17090 A EG17090 A EG 17090A EG 18951 A EG18951 A EG 18951A
Authority
EG
Egypt
Prior art keywords
pyrrolidine derivatives
chem
formula
preparing pyrrolidine
preparing
Prior art date
Application number
EG17090A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10653525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG18951(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of EG18951A publication Critical patent/EG18951A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
EG17090A 1989-03-17 1990-03-15 Process for preparing pyrrolidine derivatives EG18951A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898906166A GB8906166D0 (en) 1989-03-17 1989-03-17 Therapeutic agents

Publications (1)

Publication Number Publication Date
EG18951A true EG18951A (en) 1994-03-30

Family

ID=10653525

Family Applications (1)

Application Number Title Priority Date Filing Date
EG17090A EG18951A (en) 1989-03-17 1990-03-15 Process for preparing pyrrolidine derivatives

Country Status (37)

Country Link
US (1) US5096890B1 (ru)
EP (1) EP0388054B1 (ru)
JP (2) JPH0764809B2 (ru)
KR (2) KR920008166B1 (ru)
CN (1) CN1023007C (ru)
AT (1) ATE96783T1 (ru)
AU (1) AU614224B2 (ru)
BA (1) BA98300A (ru)
CA (1) CA2012295C (ru)
CL (1) CL2003002756A1 (ru)
CY (2) CY1812A (ru)
CZ (1) CZ280053B6 (ru)
DD (1) DD292911A5 (ru)
DE (2) DE69004302T2 (ru)
DK (1) DK0388054T3 (ru)
EG (1) EG18951A (ru)
ES (1) ES2060020T3 (ru)
FI (1) FI95573C (ru)
GB (1) GB8906166D0 (ru)
HK (1) HK130294A (ru)
HU (2) HU217433B (ru)
IE (1) IE62515B1 (ru)
IL (1) IL93694A (ru)
LU (1) LU91161I2 (ru)
MX (1) MX9319890A (ru)
MY (1) MY105527A (ru)
NL (1) NL300191I2 (ru)
NO (2) NO176316C (ru)
NZ (1) NZ232958A (ru)
PL (1) PL164136B1 (ru)
PT (1) PT93443B (ru)
RU (2) RU1833374C (ru)
SG (1) SG143394G (ru)
SK (1) SK129590A3 (ru)
UA (1) UA18263A (ru)
YU (1) YU47587B (ru)
ZA (1) ZA901982B (ru)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932594A (en) * 1988-11-01 1999-08-03 Pfizer, Inc. Muscarinic receptor antagonists
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
GB8928042D0 (en) * 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
US5607950A (en) * 1990-01-06 1997-03-04 Pfizer Inc. Muscarinic receptor antagonists
US5486527A (en) * 1990-01-06 1996-01-23 Pfizer Inc. Anticholinergic agents
CA2134077C (en) * 1992-04-23 2002-05-21 Thaddeus R. Nieduzak 4-imidomethyl-1-[2'phenyl-2'oxoethyl-]piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
US6017931A (en) * 1994-03-01 2000-01-25 Fmc Corporation Insecticidal compositions containing n-(substituted phenylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
US5639763A (en) * 1994-03-01 1997-06-17 Fmc Corporation Insecticidal N-(substituted arylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
AU704085B2 (en) * 1994-07-27 1999-04-15 Vanderbilt University Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
US5656661A (en) * 1994-07-27 1997-08-12 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5672620A (en) * 1996-02-01 1997-09-30 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
US5684031A (en) * 1996-02-01 1997-11-04 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
CN1104239C (zh) * 1996-12-02 2003-04-02 杏林制药株式会社 新颖的n－取代的吡咯烷衍生物及其制备方法
US6131129A (en) * 1997-07-30 2000-10-10 Sony Corporation Of Japan Computer system within an AV/C based media changer subunit providing a standarized command set
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
MXPA04003865A (es) * 2001-10-26 2004-07-08 Upjohn Co Compuestos de amonio cuaternario y sus usos como agentes antimuscarinicos.
SE0103668D0 (sv) * 2001-11-02 2001-11-02 Astrazeneca Ab Method for the treatment of overactive blader
JP2005511582A (ja) * 2001-11-05 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 抗ムスカリン・エアゾール
GB0129962D0 (en) * 2001-12-14 2002-02-06 Pfizer Ltd Method of treatment
GB0207104D0 (en) 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
BR0215801A (pt) 2002-07-08 2005-05-10 Ranbaxy Lab Ltd Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
EP1546098B1 (en) 2002-07-31 2008-05-28 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US7410993B2 (en) 2002-08-09 2008-08-12 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives useful as muscarinic receptor antagonists
WO2004018422A1 (en) 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
TW200412945A (en) * 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
TW200800953A (en) 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
EP1572648B1 (en) 2002-12-10 2008-07-09 Ranbaxy Laboratories, Ltd. 3,6-disubstituted azabicyclo (3.1.0)-hexane derivatives as muscarinic receptor antagonists
WO2004056811A1 (en) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
AU2002347552A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1615887A1 (en) 2003-04-10 2006-01-18 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
JP2006514978A (ja) 2003-04-10 2006-05-18 ランバクシー ラボラトリーズ リミテッド ムスカリン受容体アンタゴニストである置換アザビシクロヘキサン誘導体
EA009387B1 (ru) 2003-04-11 2007-12-28 Рэнбакси Лабораториз Лимитед Азабициклические производные в качестве антагонистов мускаринового рецептора
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
WO2004091607A1 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Quaternary ammonium compounds and their use as antimuscarinic agents
WO2004091596A2 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
TW200510298A (en) 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
JP2007524641A (ja) 2003-07-11 2007-08-30 セラヴァンス， インコーポレーテッド 置換４−アミノ−１−ベンジルピペリジン化合物
WO2005087763A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
EP1725525A1 (en) * 2004-03-11 2006-11-29 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
WO2005092341A1 (en) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Combination therapy for lower urinary tract symptoms
BRPI0617674A2 (pt) 2005-10-19 2011-08-02 Ranbaxy Lab Ltd composições farmacêuticas e seus usos
CA2630478A1 (en) * 2005-12-27 2007-07-05 Teva Pharmaceutical Industries, Ltd Processes for preparing darifenacin hydrobromide
AR062676A1 (es) 2006-09-07 2008-11-26 Medichem Sa Procedimiento mejorado para preparar compuestos de pirrolidina 1,3-disustituidas
WO2008076269A2 (en) * 2006-12-13 2008-06-26 Gilead Sciences, Inc. MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS
EP2109601A2 (en) * 2007-01-05 2009-10-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
BRPI0807615A8 (pt) * 2007-02-23 2017-12-05 Theravance Inc Compostos de difenilmetil amônico quaternário úteis como antagonistas de receptor muscarínico
WO2008126106A2 (en) * 2007-04-16 2008-10-23 Manne Satyanarayana Reddy Novel and improved processes for the preparation of intermediates of darifenacin, darifenacin and its pharmaceutically acceptable salts
WO2009007853A2 (en) * 2007-06-08 2009-01-15 Actavis Group Ptc Ehf Novel polymorphs of darifenacin free base and its hydrobromide salt
AR067001A1 (es) * 2007-06-15 2009-09-30 Medichem Sa Un metodo para determinar la pureza enantiomerica de darifenacina e intermedios
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
WO2009010846A2 (en) * 2007-07-13 2009-01-22 Medichem, S.A. Amorphous form of darifenacin hydrobromide and processes for the preparation thereof
CZ300895B6 (cs) 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125430A2 (en) * 2008-03-17 2009-10-15 Matrix Laboratoires Limited Improved process for producing darifenacin
EP2261205A4 (en) * 2008-04-02 2012-06-06 Kaneka Corp PROCESS FOR PRODUCING (S) -3- (1-CYANO-1,1-DIPHENYLMETHYL) -PYRROLIDINE
US20110144354A1 (en) * 2008-09-22 2011-06-16 Watson Pharma Private Limited Process for Preparation of Darifenacin and Intermediates Used in the Process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
KR20120025519A (ko) 2009-05-15 2012-03-15 레드엑스 파마 리미티드 산화환원 약물 유도체
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
CA2796877A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
CN101857581A (zh) * 2010-06-22 2010-10-13 浙江美诺华药物化学有限公司 一种制备达非那新中间体5-(2-溴乙基)-2,3-二氢-1-苯并呋喃的方法
WO2011161504A1 (en) 2010-06-23 2011-12-29 Micro Labs Limited Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1057145A (en) * 1963-08-16 1967-02-01 Bellon Labor Sa Roger Phenylcyclohexylacetonitrile derivatives
US4002766A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated Antiarrhythmia methods
US4242261A (en) * 1979-07-19 1980-12-30 A. H. Robins Company, Inc. Production of methylene-cycloamines
US4594343A (en) * 1984-10-19 1986-06-10 Shanklin Jr James R 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
IL76583A (en) * 1984-10-19 1988-08-31 Robins Co Inc A H 1-(aminoalkyl)-alpha'alpha-diaryl pyrrolidinyl,piperidino and homopiperidino acetamides and acetonitriles and pharmaceutical compositions containing them
EP0235463A3 (en) * 1985-12-20 1990-01-17 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents
IN163948B (ru) * 1986-01-17 1988-12-10 Robins Co Inc A H

Also Published As

Publication number Publication date
EP0388054B1 (en) 1993-11-03
PT93443B (pt) 1996-02-29
ZA901982B (en) 1991-10-30
DE122005000022I2 (de) 2006-02-02
RU2015965C1 (ru) 1994-07-15
AU5140290A (en) 1990-09-20
JPH07149640A (ja) 1995-06-13
KR960015142B1 (ko) 1996-11-01
HU901580D0 (en) 1990-06-28
DE69004302T2 (de) 1994-02-24
FI95573B (fi) 1995-11-15
NZ232958A (en) 1992-05-26
AU614224B2 (en) 1991-08-22
CA2012295C (en) 1996-11-12
UA18263A (ru) 1997-12-25
HUT58313A (en) 1992-02-28
CY2005005I2 (el) 2010-07-28
YU47587B (sh) 1995-10-24
NL300191I2 (nl) 2005-08-01
DE122005000022I1 (de) 2005-08-04
KR900014367A (ko) 1990-10-23
ATE96783T1 (de) 1993-11-15
EP0388054A1 (en) 1990-09-19
ES2060020T3 (es) 1994-11-16
NO176316C (no) 1995-03-15
RU1833374C (ru) 1993-08-07
SG143394G (en) 1995-01-13
HK130294A (en) 1994-12-02
SK278434B6 (en) 1997-05-07
IL93694A (en) 1994-08-26
SK129590A3 (en) 1997-05-07
MX9319890A (es) 1993-08-01
CL2003002756A1 (es) 2005-02-11
PT93443A (pt) 1990-11-07
IL93694A0 (en) 1990-12-23
YU52790A (sh) 1992-07-20
CY1812A (en) 1995-10-20
MY105527A (en) 1994-10-31
US5096890A (en) 1992-03-17
IE900955L (en) 1990-09-17
DE69004302D1 (de) 1993-12-09
DD292911A5 (de) 1991-08-14
IE62515B1 (en) 1995-02-08
NO2005008I2 (no) 2006-11-27
PL164136B1 (pl) 1994-06-30
GB8906166D0 (en) 1989-05-04
KR920008166B1 (ko) 1992-09-24
DK0388054T3 (da) 1993-12-06
LU91161I2 (fr) 2005-06-13
JPH02282360A (ja) 1990-11-19
FI901333A0 (fi) 1990-03-16
NO176316B (no) 1994-12-05
NO901241D0 (no) 1990-03-16
HU217433B (hu) 2000-01-28
CN1045580A (zh) 1990-09-26
HU211640A9 (en) 1995-12-28
NL300191I1 (nl) 2005-07-01
US5096890B1 (en) 1995-03-28
NO2005008I1 (en) 2005-04-11
CZ280053B6 (cs) 1995-10-18
BA98300A (bs) 2001-09-14
CY2005005I1 (el) 2010-07-28
CA2012295A1 (en) 1990-09-17
CN1023007C (zh) 1993-12-08
NO901241L (no) 1990-09-18
FI95573C (fi) 1996-02-26
JPH0764809B2 (ja) 1995-07-12
CZ129590A3 (en) 1995-05-17

Similar Documents

Publication Publication Date Title
US5096890B1 (en) Pyrrolidine derivatives
FI922343A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten piperidiini- ja pyrrolidiinijohdannaisten valmistamiseksi
FI97468B (fi) Menetelmä terapeuttisesti aktiivisten piperidiinijohdannaisten valmistamiseksi
FI922835A0 (fi) Menetelmä terapeuttisesti aktiivisten piperidiinijohdannaisten valmistamiseksi
CA2069931A1 (en) Muscarinic receptor antagonists